JP2024534471A5 - - Google Patents
Info
- Publication number
- JP2024534471A5 JP2024534471A5 JP2024517059A JP2024517059A JP2024534471A5 JP 2024534471 A5 JP2024534471 A5 JP 2024534471A5 JP 2024517059 A JP2024517059 A JP 2024517059A JP 2024517059 A JP2024517059 A JP 2024517059A JP 2024534471 A5 JP2024534471 A5 JP 2024534471A5
- Authority
- JP
- Japan
- Prior art keywords
- il9ra
- domain
- human
- mouse
- intracellular signaling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245400P | 2021-09-17 | 2021-09-17 | |
| US202163245386P | 2021-09-17 | 2021-09-17 | |
| US63/245,386 | 2021-09-17 | ||
| US63/245,400 | 2021-09-17 | ||
| PCT/US2022/076611 WO2023044456A1 (en) | 2021-09-17 | 2022-09-16 | Interleukin-9 signaling in chimeric antigen receptor (car) immune cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534471A JP2024534471A (ja) | 2024-09-20 |
| JP2024534471A5 true JP2024534471A5 (https=) | 2025-09-17 |
Family
ID=85573151
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516765A Pending JP2024534417A (ja) | 2021-09-17 | 2022-09-16 | インターロイキン－９受容体シグナル伝達ドメインを含むキメラ抗原受容体 |
| JP2024517059A Pending JP2024534471A (ja) | 2021-09-17 | 2022-09-16 | キメラ抗原受容体（ｃａｒ）免疫細胞におけるインターロイキン－９シグナル伝達 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516765A Pending JP2024534417A (ja) | 2021-09-17 | 2022-09-16 | インターロイキン－９受容体シグナル伝達ドメインを含むキメラ抗原受容体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20230265147A1 (https=) |
| EP (2) | EP4402160A4 (https=) |
| JP (2) | JP2024534417A (https=) |
| KR (2) | KR20240082352A (https=) |
| AU (2) | AU2022348587A1 (https=) |
| CA (2) | CA3231615A1 (https=) |
| IL (2) | IL311206A (https=) |
| WO (2) | WO2023044456A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3966236A4 (en) * | 2019-05-07 | 2023-05-10 | The Board of Trustees of the Leland Stanford Junior University | Enhancement of polypeptides and chimeric antigen receptors via hinge domains |
| AU2022348588A1 (en) | 2021-09-17 | 2024-04-04 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| WO2025039159A1 (en) * | 2023-08-21 | 2025-02-27 | Hangzhou Hervor Therapeutics Co., Ltd | Synthetic cytokine signaling system, preparation method, and uses thereof |
| CN120058904A (zh) * | 2023-11-28 | 2025-05-30 | 中国科学院生物物理研究所 | 一种基于相分离改造嵌合抗原受体的方法及其应用 |
| WO2025132770A1 (en) * | 2023-12-22 | 2025-06-26 | Institut National de la Santé et de la Recherche Médicale | Affitins for the treatment of cancer |
| WO2025235801A1 (en) | 2024-05-08 | 2025-11-13 | City Of Hope | Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy |
| WO2025240789A1 (en) * | 2024-05-16 | 2025-11-20 | The Regents Of The University Of California | Chimeric antigen receptor targeting nectin4 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010006111A2 (en) * | 2008-07-10 | 2010-01-14 | Merck & Co., Inc. | Methods of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer |
| CA2832569A1 (en) * | 2011-04-08 | 2012-10-11 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| ES2918501T3 (es) * | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
| WO2021050752A1 (en) * | 2019-09-11 | 2021-03-18 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric orthogonal receptor proteins and methods of use |
| WO2021141986A1 (en) * | 2020-01-07 | 2021-07-15 | St. Jude Children's Research Hospital, Inc. | Chimeric gmcsf-il18 receptor |
| CA3179414A1 (en) * | 2020-04-06 | 2021-10-14 | Synthekine, Inc. | Human immune cells genomically modified to express orthogonal receptors |
| WO2021244486A1 (zh) * | 2020-06-01 | 2021-12-09 | 上海君赛生物科技有限公司 | 信号转换受体及其用途 |
| WO2022192346A1 (en) * | 2021-03-09 | 2022-09-15 | The Trustees Of The University Of Pennsylvania | Selective stimulation of t cells in solid tumors using oncolytic viral delivery of orthogonal il-2 |
| AU2022348588A1 (en) * | 2021-09-17 | 2024-04-04 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
-
2022
- 2022-09-16 EP EP22870992.9A patent/EP4402160A4/en active Pending
- 2022-09-16 WO PCT/US2022/076611 patent/WO2023044456A1/en not_active Ceased
- 2022-09-16 KR KR1020247012565A patent/KR20240082352A/ko active Pending
- 2022-09-16 CA CA3231615A patent/CA3231615A1/en active Pending
- 2022-09-16 US US17/933,052 patent/US20230265147A1/en active Pending
- 2022-09-16 JP JP2024516765A patent/JP2024534417A/ja active Pending
- 2022-09-16 JP JP2024517059A patent/JP2024534471A/ja active Pending
- 2022-09-16 AU AU2022348587A patent/AU2022348587A1/en active Pending
- 2022-09-16 KR KR1020247012564A patent/KR20240057435A/ko active Pending
- 2022-09-16 AU AU2022346040A patent/AU2022346040A1/en active Pending
- 2022-09-16 CA CA3231618A patent/CA3231618A1/en active Pending
- 2022-09-16 IL IL311206A patent/IL311206A/en unknown
- 2022-09-16 US US17/933,049 patent/US20230085834A1/en active Pending
- 2022-09-16 EP EP22870995.2A patent/EP4402163A4/en active Pending
- 2022-09-16 IL IL311356A patent/IL311356A/en unknown
- 2022-09-16 WO PCT/US2022/076605 patent/WO2023044453A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024534471A5 (https=) | ||
| Klein et al. | The present and future of bispecific antibodies for cancer therapy | |
| Goebeler et al. | Bispecific and multispecific antibodies in oncology: opportunities and challenges | |
| JP2024534417A5 (https=) | ||
| KR102879284B1 (ko) | 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도 | |
| JP2021519580A5 (https=) | ||
| JP2021514631A5 (https=) | ||
| US20190023764A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| JP2025028239A5 (https=) | ||
| JP2020517295A5 (https=) | ||
| JP2015527070A5 (https=) | ||
| RU2020135106A (ru) | Векторы экспрессии для химерных рецепторов поглощения, генетически модифицированные клетки-хозяева и их применения | |
| JP2021519301A5 (https=) | ||
| JP2021501570A5 (https=) | ||
| JP2020506700A5 (https=) | ||
| JP2017513818A5 (https=) | ||
| JP2019513347A5 (https=) | ||
| HRP20220767T1 (hr) | Liječenje raka uporabom humaniziranog kimernog receptora antigena anti-cd19 | |
| WO2012079000A4 (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
| RU2015109631A (ru) | Способ и композиции для клеточной иммунотерапии | |
| JP2017524367A5 (https=) | ||
| JP2016514462A5 (https=) | ||
| JP2018521628A5 (https=) | ||
| JP2017519502A5 (https=) | ||
| JP2021532742A5 (https=) |